SELLAS Life Sciences (SLS) Return on Invested Capital (2013 - 2017)

SELLAS Life Sciences' (SLS) quarterly Return on Invested Capital came in at 0.01% in Q4 2017, down 319.91% on a QoQ basis from 0.0% in Q3 2017.

SELLAS Life Sciences (SLS) Return on Invested Capital (2013 - 2017) Analysis & Trends

SELLAS Life Sciences (SLS) has 3 years of Return on Invested Capital data on file, last reported at 0.01% in Q4 2017.

On a quarterly basis, Return on Invested Capital changed N/A year-over-year to 0.01% in Q4 2017; TTM through Dec 2017 was 0.01%, a N/A change from a year earlier, with the FY2017 full-year figure at 0.05%, changed 0.0% from the prior year.
Return on Invested Capital for Q4 2017 stood at 0.01%, down from 0.0% in the prior quarter.
Over the last five years, Return on Invested Capital for SLS reached as high as 0.0% in Q3 2017 and fell as low as 0.11% in Q4 2013.
Historically, Return on Invested Capital has averaged 0.04% across 3 years, with a median of 0.04% in 2014.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROIC (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	0.00%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	0.04%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	SELLAS Life Sciences	3.23 Mn	3.23 Mn	-	-

Download Data